TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35688166

Group type: EXPERIMENTAL
Intervention: INSTI exposure >0 to 6 months
Number of subjects: 29340

Group type: EXPERIMENTAL
Intervention: INSTI exposure >6 to 12 months
Number of subjects: 29340

Group type: EXPERIMENTAL
Intervention: INSTI exposure >12 to 24 months
Number of subjects: 29340

Group type: EXPERIMENTAL
Intervention: INSTI exposure >24 to 36 months
Number of subjects: 29340

Group type: EXPERIMENTAL
Intervention: INSTI exposure >36 months
Number of subjects: 29340

Group type: COMPARATOR
Intervention: No INSTI exposure
Number of subjects: 29340
Study: 35688366

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35688465

Group type: EXPERIMENTAL
Intervention: SM03, an anti-CD22 recombinant IgG1 mAb
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35688469

Group type: EXPERIMENTAL
Intervention: DPC score (0-15 points) based on dialysis duration, pretransplant intact parathyroid hormone, and serum calcium level
Number of subjects: 2

Group type: COMPARATOR
Intervention: Single-time measurement of DPC score
Number of subjects: 2
Study: 35688554

Group type: EXPERIMENTAL
Intervention: DuoBody-CD40×4-1BB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DuoBody-CD40×4-1BB with PD-1 blocking antibodies
Number of subjects: 0
Study: 35688625

Group type: EXPERIMENTAL
Intervention: Genome-wide association study across five cohorts
Number of subjects: 0
Study: 35688679

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg plus erlotinib (dose levels: 50, 100, 150 mg daily)
Number of subjects: 37
Study: 35688701

Group type: EXPERIMENTAL
Intervention: Occipital Nerve Stimulation (ONS)
Number of subjects: 7
Study: 35688802

Group type: EXPERIMENTAL
Intervention: AZD4547 administered with anastrozole or letrozole
Number of subjects: 52
Study: 35689142

Group type: EXPERIMENTAL
Intervention: Day-case bariatric surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inpatient surgery
Number of subjects: 30
Study: 35689206

Group type: EXPERIMENTAL
Intervention: Xerostomia (measured by Xerostomia Inventory)
Number of subjects: 87
Study: 35689290

Group type: EXPERIMENTAL
Intervention: Literacy-adapted, electronic family history tool
Number of subjects: 0
Study: 35689453

Group type: EXPERIMENTAL
Intervention: Endoscopic Healing Index (EHI)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Endoscopic Healing Index (EHI) <20 at 6 months
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Endoscopic Healing Index (EHI) <20 (combined all time points)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Changes in EHI
Number of subjects: 131
Study: 35689544

Group type: EXPERIMENTAL
Intervention: Alvocidib administered in combination with cytarabine and mitoxantrone (ACM) for R/R AML
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alvocidib administered in combination with cytarabine/daunorubicin (A + 7 + 3) for newly diagnosed AML
Number of subjects: 0
Study: 35689597

Group type: EXPERIMENTAL
Intervention: Upper airway stimulation (UAS) treatment
Number of subjects: 24
Study: 35689737

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily for 16 weeks in addition to existing topical therapy
Number of subjects: 152
Study: 35689793

Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nonsurgical (NS) controls
Number of subjects: 64
Study: 35690072

Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg per day and intravenous atezolizumab 1200 mg once every 3 weeks
Number of subjects: 132
Study: 35690303

Group type: EXPERIMENTAL
Intervention: Modification of obstetrical practice to offset risk for CM
Number of subjects: 0
Study: 35690498

Group type: EXPERIMENTAL
Intervention: Niraparib + bevacizumab
Number of subjects: 105
Study: 35690537

Group type: EXPERIMENTAL
Intervention: CT lung imaging measurements and conventional demographic and clinical measurements
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: CT measurements alone
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Demographic and lung function measurements alone
Number of subjects: 527
Study: 35690720

Group type: EXPERIMENTAL
Intervention: EHR phenotype algorithm for identifying ADHD cases
Number of subjects: 51293

Group type: EXPERIMENTAL
Intervention: Inclusion of ADHD-specific medications in the algorithm
Number of subjects: 51293

Group type: EXPERIMENTAL
Intervention: ICD codes and medication searches
Number of subjects: 51293

Group type: COMPARATOR
Intervention: Control group (subjects without psychiatric and neurological disorders)
Number of subjects: 51293
Study: 35690762

Group type: EXPERIMENTAL
Intervention: First-line ART
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Not switching ART regimen
Number of subjects: 347

Group type: COMPARATOR
Intervention: Switching ART regimen
Number of subjects: 347
Study: 35690798

Group type: EXPERIMENTAL
Intervention: Current cannabis use
Number of subjects: 6348

Group type: EXPERIMENTAL
Intervention: Former cannabis use
Number of subjects: 6348
Study: 35690827

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 60

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 60
Study: 35690891

Group type: EXPERIMENTAL
Intervention: 28 days of cannabis abstinence facilitated by contingency management, motivational interviewing, psychoeducation, and coping-skills training
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 28 days of cannabis abstinence
Number of subjects: 11
Study: 35690924

Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 73
Study: 35691028

Group type: EXPERIMENTAL
Intervention: Therapeutic approaches recommended by the Spanish Society of Transplantation (SET), GESITRA-SEIMC, and REIPI for managing MDR GNB infections in SOT recipients.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multinational INCREMENT-SOT consortium findings.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recently approved antibiotics positioning in SOT setting.
Number of subjects: 0
Study: 35691544

Group type: EXPERIMENTAL
Intervention: CC-99677, a selective targeted covalent MK2 inhibitor
Number of subjects: 0
Study: 35691614

Group type: EXPERIMENTAL
Intervention: Digital interventions (e.g., electronic monitoring devices, short message services)
Number of subjects: 15207

Group type: EXPERIMENTAL
Intervention: Digital interventions
Number of subjects: 15207
Study: 35692051

Group type: COMPARATOR
Intervention: Case-control study using questionnaires on candidate risk factors for GC
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Case-control tissue sampling study using proteome, genome, microbiome, and immune analyses
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Educational study testing knowledge dissemination on GC risk factors and symptoms
Number of subjects: 2400
Study: 35692260

Group type: EXPERIMENTAL
Intervention: Azithromycin (20 mg/kg)
Number of subjects: 21832

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21832
Study: 35692547

Group type: EXPERIMENTAL
Intervention: ADR-001
Number of subjects: 6
Study: 35692935

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electric Nerve Stimulation (TENS)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 35693790

Group type: EXPERIMENTAL
Intervention: Saturated Fatty Acids (SFAs) in case children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polyunsaturated Fatty Acids (PUFAs) in control children
Number of subjects: 0
Study: 35693874

Group type: EXPERIMENTAL
Intervention: Nonavalent HPV vaccine
Number of subjects: 2275

Group type: EXPERIMENTAL
Intervention: Bivalent HPV vaccine
Number of subjects: 2275

Group type: COMPARATOR
Intervention: Meningococcal vaccine
Number of subjects: 2275
Study: 35694160

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flavanone-free control drink
Number of subjects: 0
Study: 35694163

Group type: EXPERIMENTAL
Intervention: Intermittent fasting combined with exercise (IF + EX)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Exercise group (EX)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intermittent fasting group (IF)
Number of subjects: 36
Study: 35694168

Group type: EXPERIMENTAL
Intervention: Mastery measured with the Pearlin Mastery Scale (PMS)
Number of subjects: 32588
Study: 35694435

Group type: EXPERIMENTAL
Intervention: Trait mindfulness (measured by the Five Facet Mindfulness Questionnaire and the Decentering subscale of the Experiences Questionnaire)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Trait mindfulness
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Mindfulness-based interventions
Number of subjects: 153
Study: 35694653

Group type: EXPERIMENTAL
Intervention: Stepped Care and Collaborative Model (SCCM)
Number of subjects: 584

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 584
Study: 35694680

Group type: EXPERIMENTAL
Intervention: 100% chitosan bioactive hemostatic dressing
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Potassium-ferrate based topical hemostasis disc
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard pneumatic airbladder-based compression device
Number of subjects: 600
Study: 35694826

Group type: EXPERIMENTAL
Intervention: Abnormal CFR (Coronary Flow Reserve)
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Structural CMD (abnormal CFR with abnormal MR)
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Functional CMD (abnormal CFR with normal MR)
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Normal microvascular function
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Microvascular resistance parameters
Number of subjects: 1102
Study: 35695002

Group type: EXPERIMENTAL
Intervention: Bevacizumab and FOLFIRI in combination with daily oral G-NLC (ginsenoside-modified nanostructured lipid carrier containing curcumin)
Number of subjects: 44
Study: 35695137

Group type: EXPERIMENTAL
Intervention: App for detecting atrial fibrillation
Number of subjects: 0
Study: 35695332

Group type: EXPERIMENTAL
Intervention: Clopidogrel Discontinuation Group
Number of subjects: 3456

Group type: COMPARATOR
Intervention: Non-Clopidogrel Discontinuation Group
Number of subjects: 3456

Group type: EXPERIMENTAL
Intervention: CYP2C19 subgroup analysis
Number of subjects: 3456
Study: 35695334

Group type: EXPERIMENTAL
Intervention: Systemic JAK inhibitors plus standard of care
Number of subjects: 11145
Study: 35695536

Group type: EXPERIMENTAL
Intervention: Recombinant NDV (rNDV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality control assays for rNDV
Number of subjects: 0
Study: 35695563

Group type: EXPERIMENTAL
Intervention: Entrectinib in combination with endocrine therapy
Number of subjects: 0
Study: 35695609

Group type: EXPERIMENTAL
Intervention: High expression of NUSAP1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NUSAP1 expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NUSAP1
Number of subjects: 0
Study: 35695616

Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium (4 mg/day) for 180 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 12
Study: 35695646

Group type: EXPERIMENTAL
Intervention: Antidepressant combinations
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Baseline clinical characteristics (insomnia, reduced need for sleep, self-confidence, cheerfulness, comorbid panic disorder)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Combination of baseline SI and insomnia
Number of subjects: 198
Study: 35695943

Group type: EXPERIMENTAL
Intervention: Accuryn Monitoring System (Potrero Medical, Hayward, CA) for continuous urinary output (CUO) and intra-abdominal pressure (IAP) measurements
Number of subjects: 137
Study: 35696069

Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control (no rhPTH(1-84))
Number of subjects: 113
Study: 35696133

Group type: EXPERIMENTAL
Intervention: 44-channel suprachoroidal retinal prosthesis with a stimulation charge density limited to 32 µC/cm2 per phase
Number of subjects: 4
Study: 35696157

Group type: EXPERIMENTAL
Intervention: 10 mg/ml protonated nicotine at 15 W
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 10 mg/ml protonated nicotine at 30 W
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 15 mg/ml protonated nicotine at 15 W
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 15 mg/ml protonated nicotine at 30 W
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 30 mg/ml protonated nicotine at 15 W
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 30 mg/ml protonated nicotine at 30 W
Number of subjects: 45
Study: 35696182

Group type: EXPERIMENTAL
Intervention: Lipodystrophy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Receptoropathy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ovary+ patients
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ovary- patients
Number of subjects: 18

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 18
Study: 35696702

Group type: EXPERIMENTAL
Intervention: Neoadjuvant cetuximab followed by concurrent radiotherapy with cetuximab 250 mg/m2/cisplatin 40 mg/m2 (DL1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Radiotherapy with cetuximab 200 mg/m2 and cisplatin 30 mg/m2 (DL2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Radiotherapy with cetuximab 250 mg/m2 and cisplatin 30 mg/m2 (DL3)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Neoadjuvant cetuximab
Number of subjects: 21
Study: 35697255

Group type: EXPERIMENTAL
Intervention: Rivaroxaban underdose (10 mg/d)
Number of subjects: 2215

Group type: COMPARATOR
Intervention: Rivaroxaban standard-dose (15 mg/d)
Number of subjects: 2215
Study: 35697266

Group type: EXPERIMENTAL
Intervention: Esophageal sponge cytology
Number of subjects: 22
Study: 35697332

Group type: EXPERIMENTAL
Intervention: Vebicorvir (VBR) 300 mg + Entecavir (ETV) 0.5 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (PBO) + Entecavir (ETV) 0.5 mg
Number of subjects: 25
Study: 35697530

Group type: EXPERIMENTAL
Intervention: Uterus transplantation (UTx)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: In vitro fertilization with embryo transfer (ET)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: In vitro fertilization with day 2 embryos
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: In vitro fertilization with day 5 embryos
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pregnancy outcomes
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Delivery outcomes
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Long-term health measures
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Psychosocial outcomes
Number of subjects: 9
Study: 35697532

Group type: EXPERIMENTAL
Intervention: Assisted reproductive technology (ART)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Ovulation induction (OI)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Twins conceived using ART or OI
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Twins conceived using OI
Number of subjects: 559

Group type: COMPARATOR
Intervention: Children conceived using ART or OI
Number of subjects: 559
Study: 35697729

Group type: EXPERIMENTAL
Intervention: Fish oil emulsion (FO) adjunct to 3+7 chemotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Historical comparison to LAM2001 trial
Number of subjects: 30
Study: 35697890

Group type: EXPERIMENTAL
Intervention: Catheter ablation of premature ventricular contractions (PVC)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Catheter ablation of ventricular tachycardia (VT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Intensified medical therapy
Number of subjects: 64
Study: 35698155

Group type: EXPERIMENTAL
Intervention: DEXA+ (dexamethasone 6 mg/day intravenous for 10 days)
Number of subjects: 158

Group type: COMPARATOR
Intervention: DEXA- (not treated with corticosteroids)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: DEXA+
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: VAP (in general)
Number of subjects: 158
Study: 35698201

Group type: EXPERIMENTAL
Intervention: Sepsis-associated critical illness
Number of subjects: 888

Group type: COMPARATOR
Intervention: Non-sepsis-associated critical illness
Number of subjects: 888
Study: 35698232

Group type: EXPERIMENTAL
Intervention: Bromocriptine (pre-treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ER/SR calcium depletion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MANF (mesencephalic astrocyte-derived neurotrophic factor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SEPN1 (Selenoprotein N)
Number of subjects: 0
Study: 35698233

Group type: EXPERIMENTAL
Intervention: Double Valve Replacement (DVR)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Aortic Valve Replacement with Mitral Valve Repair (AVR + MVP)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both surgical techniques (DVR and AVR + MVP)
Number of subjects: 89
Study: 35698288

Group type: EXPERIMENTAL
Intervention: Active Surveillance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35698581

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for 52 weeks
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 35698787

Group type: EXPERIMENTAL
Intervention: Wilcoxon-Mann-Whitney test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brunner-Munzel test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test procedure based on the log win odds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modification of the win ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FREEDOMS clinical trial methodology
Number of subjects: 0
Study: 35698835

Group type: EXPERIMENTAL
Intervention: ChAdOx1-BNT162b2 (AZ-Pf group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: ChAdOx1 (AZ-AZ group)
Number of subjects: 31
Study: 35698886

Group type: EXPERIMENTAL
Intervention: Cervical Vestibular Evoked Myogenic Potentials with bone-conduction as a vestibular screening tool
Number of subjects: 254
Study: 35698971

Group type: EXPERIMENTAL
Intervention: Early venous filling (EVF) evaluated by 2 blinded readers
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Time-Alberta Stroke Program Early CT-Glycemia-EVF score
Number of subjects: 909
Study: 35699077

Group type: EXPERIMENTAL
Intervention: VSV-GP (BI 1831169)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VSV-GP (BI 1831169) combined with ezabenlimab (BI 754091)
Number of subjects: 0
Study: 35699183

Group type: EXPERIMENTAL
Intervention: Surgical closure of atrial septal defect (n=33)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Surgical closure of ventricular septal defect (n=29)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy matched controls (n=38)
Number of subjects: 62
Study: 35699443

Group type: EXPERIMENTAL
Intervention: Cochleated Amphotericin B (CAMB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35699482

Group type: EXPERIMENTAL
Intervention: Remote ambulatory cardiac monitoring (rACM) for 2 weeks pre- and post-TAVI
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Remote ambulatory cardiac monitoring (rACM)
Number of subjects: 192
Study: 35699578

Group type: EXPERIMENTAL
Intervention: Deep learning-based cardiac MRI measurements
Number of subjects: 539
Study: 35699910

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (SGLT2 inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35699949

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes mellitus (T1DM) participants
Number of subjects: 416

Group type: COMPARATOR
Intervention: Control subjects without diabetes
Number of subjects: 416
Study: 35699976

Group type: EXPERIMENTAL
Intervention: High agency (perceived control over the outcome)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Low agency (no control over the outcome)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: High immediacy (short-term negative health outcome)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Low immediacy (long-term negative health outcome)
Number of subjects: 178
Study: 35699977

Group type: EXPERIMENTAL
Intervention: Direct-to-patient digital research platform (Eureka Research Platform) for onboarding, consent, and activities in the digital study.
Number of subjects: 907
Study: 35700000

Group type: EXPERIMENTAL
Intervention: Preprocedural immersive virtual reality (IVR) game preparation (IMAGINE)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Usual care (standard care as per the radiology department's protocol)
Number of subjects: 98
Study: 35700019

Group type: EXPERIMENTAL
Intervention: 8-week physical activity program
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 110
Study: 35700023

Group type: EXPERIMENTAL
Intervention: Health promotion program promoting HPV vaccination (information to students and parents, training of general practitioners, free school-based vaccination)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Control group (students from another middle school who will not attend the program)
Number of subjects: 504
Study: 35700020

Group type: EXPERIMENTAL
Intervention: NiteCAPP CARES (web-based cognitive behavioral therapy for insomnia)
Number of subjects: 100

Group type: COMPARATOR
Intervention: NiteCAPP SHARES (web-based sleep hygiene control)
Number of subjects: 100
Study: 35700026

Group type: EXPERIMENTAL
Intervention: Rural D1D (R-D1D) program, a culturally adapted virtual DSMES program for rural populations.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard patient education (control group).
Number of subjects: 64
Study: 35700142

Group type: EXPERIMENTAL
Intervention: Finerenone 10 mg or 20 mg plus empagliflozin 10 mg
Number of subjects: 807

Group type: COMPARATOR
Intervention: Empagliflozin 10 mg alone
Number of subjects: 807

Group type: COMPARATOR
Intervention: Finerenone 10 mg or 20 mg alone
Number of subjects: 807
Study: 35701056

Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (cMDA)
Number of subjects: 48
Study: 35701182

Group type: EXPERIMENTAL
Intervention: Abrocitinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abrocitinib, M1, M2
Number of subjects: 0
Study: 35701185

Group type: EXPERIMENTAL
Intervention: Cladribine tablets 3.5 mg/kg
Number of subjects: 270
Study: 35701296

Group type: EXPERIMENTAL
Intervention: Omentectomy
Number of subjects: 54
Study: 35701384

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 12